entertainment -WSS

entertainment

author：comprehensive 2025-09-28 07:07:52 - browse：33318

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Eli Lilly, Pfizer, and others want in on the online prescription market

focus

WSS

Drinking less cuts risk of oral cavity, esophageal cancer: Report

In Spain, a hospital brews its own CAR

What STAT readers think about the FDA and patient advocacy

Readout Newsletter: Merck, J&J, and long Covid

Keeping primary care docs in field isn't impossible, says AAFP CEO

Hospitals owned by private equity see complications spike 25%

knowledge

entertainment

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

NIH director takes cautious approach to Biden drug pricing priority

Wildfire smoke exposes gaps in outdoor worker protections

HCA sued by state AG for quality issues at Mission Health

Moonlake's readout produced a cash windfall. Risks remain

HCA sued by state AG for quality issues at Mission Health

Hollywood unions extend contract negotiations for actors

My yearlong odyssey to get my son’s ADHD medication covered

What does generative AI mean for health care? We asked experts

Can sheer will power keep patients alive in their dying hours?

leisure time

Why doctors need education on FDA device approval process

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Dewpoint Therapeutics lays off staff after losing partnerships

Hospitals owned by private equity see complications spike 25%

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

HCA sued by state AG for quality issues at Mission Health

hotspot

explore

focus

focus